MV Blagosklonny

904 total citations
9 papers, 773 citations indexed

About

MV Blagosklonny is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, MV Blagosklonny has authored 9 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Oncology and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in MV Blagosklonny's work include Cell death mechanisms and regulation (4 papers), Acute Lymphoblastic Leukemia research (2 papers) and Microtubule and mitosis dynamics (2 papers). MV Blagosklonny is often cited by papers focused on Cell death mechanisms and regulation (4 papers), Acute Lymphoblastic Leukemia research (2 papers) and Microtubule and mitosis dynamics (2 papers). MV Blagosklonny collaborates with scholars based in United States and Malaysia. MV Blagosklonny's co-authors include Tito Fojo, Raymond C. Bergan, Yoshiro Chuman, William D. Figg, Kapil N. Bhalla, Franck Housseau, Yaqing Liu, Edward Kyle, Sajni Patel and Frances T. Hakim and has published in prestigious journals such as Leukemia and Prostate Cancer and Prostatic Diseases.

In The Last Decade

MV Blagosklonny

9 papers receiving 757 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
MV Blagosklonny United States	9	547	185	112	103	89	9	773
Dariush Farahi Far France	12	522 1.0×	322 1.7×	167 1.5×	92 0.9×	85 1.0×	16	811
R A Rifkind United States	14	651 1.2×	221 1.2×	102 0.9×	70 0.7×	78 0.9×	16	917
Martin Loignon Canada	17	604 1.1×	272 1.5×	71 0.6×	66 0.6×	40 0.4×	29	866
Margaret S. Dordal United States	10	432 0.8×	129 0.7×	215 1.9×	50 0.5×	153 1.7×	12	822
Kylie A. Hotchkiss United States	12	622 1.1×	224 1.2×	136 1.2×	214 2.1×	75 0.8×	13	1.0k
Antony Letai United States	11	545 1.0×	303 1.6×	104 0.9×	81 0.8×	55 0.6×	11	840
Anna Fantozzi Italy	9	542 1.0×	287 1.6×	83 0.7×	50 0.5×	155 1.7×	9	792
Wendy L. Devereux United States	13	1.1k 2.0×	450 2.4×	71 0.6×	54 0.5×	77 0.9×	13	1.4k
Banibrata Sen United States	15	555 1.0×	358 1.9×	85 0.8×	96 0.9×	59 0.7×	21	923
Catherine Tang United States	12	602 1.1×	201 1.1×	89 0.8×	99 1.0×	234 2.6×	16	1.1k

Countries citing papers authored by MV Blagosklonny

Since Specialization

Citations

This map shows the geographic impact of MV Blagosklonny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by MV Blagosklonny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites MV Blagosklonny more than expected).

Fields of papers citing papers by MV Blagosklonny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by MV Blagosklonny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by MV Blagosklonny. The network helps show where MV Blagosklonny may publish in the future.

Co-authorship network of co-authors of MV Blagosklonny

This figure shows the co-authorship network connecting the top 25 collaborators of MV Blagosklonny. A scholar is included among the top collaborators of MV Blagosklonny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with MV Blagosklonny. MV Blagosklonny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Blagosklonny, MV. (2002). STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’. Leukemia. 16(4). 570–572. 31 indexed citations

2.

Blagosklonny, MV. (2002). Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia. 16(4). 455–462. 201 indexed citations

3.

Blagosklonny, MV. (2001). Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia. 15(6). 936–941. 79 indexed citations

4.

Blagosklonny, MV. (2001). Unwinding the loop of Bcl-2 phosphorylation. Leukemia. 15(6). 869–874. 116 indexed citations

5.

Liu, Yaqing, Edward Kyle, Sajni Patel, et al.. (2001). Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. Prostate Cancer and Prostatic Diseases. 4(2). 81–91. 25 indexed citations

6.

Blagosklonny, MV, et al.. (2001). The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 15(10). 1537–1543. 107 indexed citations

7.

Blagosklonny, MV. (2000). Cell death beyond apoptosis. Leukemia. 14(8). 1502–1508. 116 indexed citations

8.

Blagosklonny, MV, Yoshiro Chuman, Raymond C. Bergan, & Tito Fojo. (1999). Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia. 13(7). 1028–1036. 66 indexed citations

9.

Blagosklonny, MV. (1999). Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal. Leukemia. 13(12). 2031–2035. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact